ArticleThe Lancet regional health. Southeast Asia2025
Effectiveness of different border control strategies for reducing mpox importation risk: a modelling study.
Article in The Lancet regional health. Southeast Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Review of Epidemiological Modeling Studies on Monkeypox.China CDC weekly · 2026Article
- Insights into Monkeypox Virus: Host Immunity, Viral Immune Evasion, Recent Advances in Vaccines, Therapeutic Development, and Future Perspectives.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Clade Ib monkeypox virus can be more transmissible through non-sexual routes compared to the previous Clade IIb strain. With imported cases sporadically reported globally, concerns have emerged about the potential of widespread transmission in the general community after importation events. Border control measures, such as screening and quarantining of arriving travellers, may help mitigate this risk and prevent localised outbreaks in the event of global spread. Methods: We developed an agent-based model to simulate individual disease progression and testing. We then evaluated the effectiveness of nine border control strategies in reducing importation risk. The simulations incorporated varying disease prevalence levels (0.001%, 0.005%, and 0.01%) in the country of origin. Findings: The proposed border-control measures would reduce missed cases by 40.1% (39.1%-41.0%), 49.8% (48.8%-50.8%), and 58.1% (57.1%-59.0%) for pre-departure, on-arrival, and both tests, respectively. Replacing the on-arrival test with a 7-day quarantine and post-quarantine testing would lower the proportion to 21.8% (20.9%-22.6%). Quarantine-only strategies showed a linear increase in effectiveness against duration, reaching a 90.4% (89.8%-91.0%) reduction with a 28-day quarantine. Interpretation: When disease prevalence in the country of origin is low (0.001%), less restrictive approaches such as single on-arrival testing or a 14-day quarantine can maintain very low imported case counts of one or below. At higher prevalences, 7-day quarantining followed by post-quarantine testing, or 28-day quarantining is required to maintain similar effects. Border management will require risk assessments between importation risk, based on origin country prevalence, and the negative impacts of control on travellers. Funding: This work was supported by Ministry of Education Reimagine Research Grant; PREPARE, Ministry of Health; the Japan Science and Technology Agency (JST) (JPMJPR22R3 to AE); the Japan Society for the Promotion of Science (JSPS) (JP22K17329 to AE), and National University of Singapore Start-Up Grant (to AE); Nanyang Technological University, Singapore-Imperial Research Collaboration Fund (INCF-2023-007 to JTL).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.